Injectable Nanomedicines Market

Global Market Study on Injectable Nanomedicines: Rapid Adoption of Injectable Nano-formulations in Eradicating Drug-resistant Cancers to Boost Sales

Injectable Nanomedicines Market

  • December-2018
  • PMRREP25999
  • 173 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. PMR Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Injectable Nanomedicines Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity

4. Market Background

    4.1. Market Dynamics

        4.1.1. Drivers

        4.1.2. Restraints

        4.1.3. Trends

5. Key Inclusions

    5.1. Nanomedicines Development Over Time

    5.2. Regulatory Scenario

    5.3. Disease Epidemiology

    5.4. Approvals of Commercial Injectable Nanomedicines

6. North America Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    6.1. Introduction

    6.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

        6.2.1. U.S.

        6.2.2. Canada

    6.3. Market Size (US$ Mn) Forecast By Country, 2018–2026

    6.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        6.4.1. Liposomes

        6.4.2. Micelles

        6.4.3. Nanocrystals

        6.4.4. Polymeric Nanoparticles

        6.4.5. Metallic Nanoparticles

        6.4.6. Mesoporous Silica Nanoparticles

        6.4.7. Others

    6.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    6.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013–2017

        6.6.1. Cancers

        6.6.2. Central Nervous System Diseases

        6.6.3. Cardiovascular diseases

        6.6.4. Infection Control

        6.6.5. Inflammatory Diseases

        6.6.6. Others

    6.7. Market Size (US$ Mn) Forecast By Application, 2018–2026

    6.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        6.8.1. Hospitals

        6.8.2. Ambulatory Surgical Centers

        6.8.3. Clinics

        6.8.4. Specialized Drugs R&D Institutes

        6.8.5. Managed Care Organizations

    6.9. Market Size (US$ Mn) Forecast By End User, 2018–2026

    6.10. Market Attractiveness Analysis

        6.10.1. By Country

        6.10.2. By Drug Type

        6.10.3. By Application

        6.10.4. By End User

7. Latin America Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    7.1. Introduction

    7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

        7.2.1. Brazil

        7.2.2. Mexico

        7.2.3. Rest of Latin America

    7.3. Market Size (US$ Mn) Forecast By Country, 2018–2026

    7.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        7.4.1. Liposomes

        7.4.2. Micelles

        7.4.3. Nanocrystals

        7.4.4. Polymeric Nanoparticles

        7.4.5. Metallic Nanoparticles

        7.4.6. Mesoporous Silica Nanoparticles

        7.4.7. Others

    7.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    7.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013–2017

        7.6.1. Cancers

        7.6.2. Central Nervous System Diseases

        7.6.3. Cardiovascular diseases

        7.6.4. Infection Control

        7.6.5. Inflammatory Diseases

        7.6.6. Others

    7.7. Market Size (US$ Mn) Forecast By Application, 2018–2026

    7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        7.8.1. Hospitals

        7.8.2. Ambulatory Surgical Centers

        7.8.3. Clinics

        7.8.4. Specialized Drugs R&D Institutes

        7.8.5. Managed Care Organizations

    7.9. Market Size (US$ Mn) Forecast By End User, 2018–2026

    7.10. Market Attractiveness Analysis

        7.10.1. By Country

        7.10.2. By Drug Type

        7.10.3. By Application

        7.10.4. By End User

8. Europe Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    8.1. Introduction

    8.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

        8.2.1. Germany

        8.2.2. U.K.

        8.2.3. France

        8.2.4. Italy

        8.2.5. Spain

        8.2.6. Russia

        8.2.7. Rest of Europe

    8.3. Market Size (US$ Mn) Forecast By Country, 2018–2026

    8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        8.4.1. Liposomes

        8.4.2. Micelles

        8.4.3. Nanocrystals

        8.4.4. Polymeric Nanoparticles

        8.4.5. Metallic Nanoparticles

        8.4.6. Mesoporous Silica Nanoparticles

        8.4.7. Others

    8.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    8.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013–2017

        8.6.1. Cancers

        8.6.2. Central Nervous System Diseases

        8.6.3. Cardiovascular diseases

        8.6.4. Infection Control

        8.6.5. Inflammatory Diseases

        8.6.6. Others

    8.7. Market Size (US$ Mn) Forecast By Application, 2018–2026

    8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        8.8.1. Hospitals

        8.8.2. Ambulatory Surgical Centers

        8.8.3. Clinics

        8.8.4. Specialized Drugs R&D Institutes

        8.8.5. Managed Care Organizations

    8.9. Market Size (US$ Mn) Forecast By End User, 2018–2026

    8.10. Market Attractiveness Analysis

        8.10.1. By Country

        8.10.2. By Drug Type

        8.10.3. By Application

        8.10.4. By End User

9. Asia Pacific Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

        9.2.1. Japan

        9.2.2. China

        9.2.3. India

        9.2.4. Australia and New Zealand

        9.2.5. Rest of Asia Pacific

    9.3. Market Size (US$ Mn) Forecast By Country, 2018–2026

    9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        9.4.1. Liposomes

        9.4.2. Micelles

        9.4.3. Nanocrystals

        9.4.4. Polymeric Nanoparticles

        9.4.5. Metallic Nanoparticles

        9.4.6. Mesoporous Silica Nanoparticles

        9.4.7. Others

    9.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    9.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013–2017

        9.6.1. Cancers

        9.6.2. Central Nervous System Diseases

        9.6.3. Cardiovascular diseases

        9.6.4. Infection Control

        9.6.5. Inflammatory Diseases

        9.6.6. Others

    9.7. Market Size (US$ Mn) Forecast By Application, 2018–2026

    9.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        9.8.1. Hospitals

        9.8.2. Ambulatory Surgical Centers

        9.8.3. Clinics

        9.8.4. Specialized Drugs R&D Institutes

        9.8.5. Managed Care Organizations

    9.9. Market Size (US$ Mn) Forecast By End User, 2018–2026

    9.10. Market Attractiveness Analysis

        9.10.1. By Country

        9.10.2. By Drug Type

        9.10.3. By Application

        9.10.4. By End User

10. Middle East & Africa Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

        10.2.1. GCC Countries

        10.2.2. South Africa

        10.2.3. Rest of MEA

    10.3. Market Size (US$ Mn) Forecast By Country, 2018–2026

    10.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        10.4.1. Liposomes

        10.4.2. Micelles

        10.4.3. Nanocrystals

        10.4.4. Polymeric Nanoparticles

        10.4.5. Metallic Nanoparticles

        10.4.6. Mesoporous Silica Nanoparticles

        10.4.7. Others

    10.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    10.6. Historical Market Value (US$ Mn) Trend Analysis By Application, 2013–2017

        10.6.1. Cancers

        10.6.2. Central Nervous System Diseases

        10.6.3. Cardiovascular diseases

        10.6.4. Infection Control

        10.6.5. Inflammatory Diseases

        10.6.6. Others

    10.7. Market Size (US$ Mn) Forecast By Application, 2018–2026

    10.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        10.8.1. Hospitals

        10.8.2. Ambulatory Surgical Centers

        10.8.3. Clinics

        10.8.4. Specialized Drugs R&D Institutes

        10.8.5. Managed Care Organizations

    10.9. Market Size (US$ Mn) Forecast By End User, 2018–2026

    10.10. Market Attractiveness Analysis

        10.10.1. By Country

        10.10.2. By Drug Type

        10.10.3. By Application

        10.10.4. By End User

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Market Structure Analysis

    13.1. Market Structure by Tier of Companies

14. Competition Analysis

    14.1. Competition Dashboard

    14.2. Company Deep Dive

        14.2.1. Merck & Co., Inc.

            14.2.1.1. Overview

            14.2.1.2. Product and Technology Portfolio

            14.2.1.3. Production Footprint

            14.2.1.4. Sales Footprint

            14.2.1.5. Channel Footprint

            14.2.1.6. Strategy

                14.2.1.6.1. Marketing Strategy

                14.2.1.6.2. Drug Strategy

                14.2.1.6.3. Channel Strategy

        14.2.2. Lupin

            14.2.2.1. Overview

            14.2.2.2. Product and Technology Portfolio

            14.2.2.3. Production Footprint

            14.2.2.4. Sales Footprint

            14.2.2.5. Channel Footprint

            14.2.2.6. Strategy

                14.2.2.6.1. Marketing Strategy

                14.2.2.6.2. Drug Strategy

                14.2.2.6.3. Channel Strategy

        14.2.3. Pacira Pharmaceuticals Inc.

            14.2.3.1. Overview

            14.2.3.2. Product and Technology Portfolio

            14.2.3.3. Production Footprint

            14.2.3.4. Sales Footprint

            14.2.3.5. Channel Footprint

            14.2.3.6. Strategy

                14.2.3.6.1. Marketing Strategy

                14.2.3.6.2. Drug Strategy

                14.2.3.6.3. Channel Strategy

        14.2.4. Celgene Pharmaceutical Co. Ltd.

            14.2.4.1. Overview

            14.2.4.2. Product and Technology Portfolio

            14.2.4.3. Production Footprint

            14.2.4.4. Sales Footprint

            14.2.4.5. Channel Footprint

            14.2.4.6. Strategy

                14.2.4.6.1. Marketing Strategy

                14.2.4.6.2. Drug Strategy

                14.2.4.6.3. Channel Strategy

        14.2.5. Amgen, Inc.

            14.2.5.1. Overview

            14.2.5.2. Product and Technology Portfolio

            14.2.5.3. Production Footprint

            14.2.5.4. Sales Footprint

            14.2.5.5. Channel Footprint

            14.2.5.6. Strategy

                14.2.5.6.1. Marketing Strategy

                14.2.5.6.2. Drug Strategy

                14.2.5.6.3. Channel Strategy

        14.2.6. Janssen Biotech Inc. (Sub. Johnson & Johnson Services, Inc.)

            14.2.6.1. Overview

            14.2.6.2. Product and Technology Portfolio

            14.2.6.3. Production Footprint

            14.2.6.4. Sales Footprint

            14.2.6.5. Channel Footprint

            14.2.6.6. Strategy

                14.2.6.6.1. Marketing Strategy

                14.2.6.6.2. Drug Strategy

                14.2.6.6.3. Channel Strategy

        14.2.7. Pfizer Inc.

            14.2.7.1. Overview

            14.2.7.2. Product and Technology Portfolio

            14.2.7.3. Production Footprint

            14.2.7.4. Sales Footprint

            14.2.7.5. Channel Footprint

            14.2.7.6. Strategy

                14.2.7.6.1. Marketing Strategy

                14.2.7.6.2. Drug Strategy

                14.2.7.6.3. Channel Strategy

        14.2.8. Hoffmann-La Roche Ltd.

            14.2.8.1. Overview

            14.2.8.2. Product and Technology Portfolio

            14.2.8.3. Production Footprint

            14.2.8.4. Sales Footprint

            14.2.8.5. Channel Footprint

            14.2.8.6. Strategy

                14.2.8.6.1. Marketing Strategy

                14.2.8.6.2. Drug Strategy

                14.2.8.6.3. Channel Strategy

        14.2.9. Teva Pharmaceutical Industries Ltd.

            14.2.9.1. Overview

            14.2.9.2. Product and Technology Portfolio

            14.2.9.3. Production Footprint

            14.2.9.4. Sales Footprint

            14.2.9.5. Channel Footprint

            14.2.9.6. Strategy

                14.2.9.6.1. Marketing Strategy

                14.2.9.6.2. Drug Strategy

                14.2.9.6.3. Channel Strategy

        14.2.10. Bausch & Lomb Incorporated.

            14.2.10.1. Overview

            14.2.10.2. Product and Technology Portfolio

            14.2.10.3. Production Footprint

            14.2.10.4. Sales Footprint

            14.2.10.5. Channel Footprint

            14.2.10.6. Strategy

                14.2.10.6.1. Marketing Strategy

                14.2.10.6.2. Drug Strategy

                14.2.10.6.3. Channel Strategy

15. Global Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026, By Region

    15.1. Introduction/Key Findings

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2017

    15.3. Market Size (US$ Mn) Forecast By Region, 2018–2026

        15.3.1. North America

        15.3.2. Latin America

        15.3.3. Europe

        15.3.4. Asia Pacific

        15.3.5. Middle East & Africa

    15.4. Market Attractiveness Analysis By Region

16. Global Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

    16.1. Introduction/Key Findings

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017

        16.2.1. Liposomes

        16.2.2. Micelles

        16.2.3. Nanocrystals

        16.2.4. Polymeric Nanoparticles

        16.2.5. Metallic Nanoparticles

        16.2.6. Mesoporous Silica Nanoparticles

        16.2.7. Others

    16.3. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026

    16.4. Market Attractiveness Analysis By Drug Type

17. Global Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026, By Application

    17.1. Introduction/Key Findings

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2017 Orthopedic Surgery

        17.2.1. Cancers

        17.2.2. Central Nervous System Diseases

        17.2.3. Cardiovascular diseases

        17.2.4. Infection Control

        17.2.5. Inflammatory Diseases

        17.2.6. Others

    17.3. Market Size (US$ Mn) Forecast By Application, 2018–2026

    17.4. Market Attractiveness Analysis By Application

18. Global Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026, By End User

    18.1. Introduction/Key Findings

    18.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013–2017

        18.2.1. Hospitals

        18.2.2. Ambulatory Surgical Centers

        18.2.3. Clinics

        18.2.4. Specialized Drugs R&D Institutes

        18.2.5. Managed Care Organizations

    18.3. Market Size (US$ Mn) Forecast By End User, 2018–2026

    18.4. Market Attractiveness Analysis By End User

19. Global Injectable Nanomedicines Market Analysis 2013–2017 and Forecast 2018–2026

    19.1. Market Value Share Analysis By All Segment

    19.2. Y-o-Y Growth Analysis By All Segment

    19.3. Absolute $ Opportunity

20. Assumptions and Acronyms Used

21. Research Methodology

Find Out More about the Report Coverage

List of Tables

List of Tables

Table 01: Parameters For Quality And Safety Evaluation Of Nanotechnology-based Medicinal Products For Biomedical Use

Table 02: Commercial Available Injectable Nanomedicines (1/3)

Table 03: Commercial Available Injectable Nanomedicines (2/3)

Table 04: Commercial Available Injectable Nanomedicines (3/3)

Table 05: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Country

Table 06: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 07: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 08: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Table 09: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Country

Table 10: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 11: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 12: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Table 13: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Country

Table 14: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 15: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 16: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Table 17: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Country

Table 18: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 19: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 20: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Table 21: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Country

Table 22: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 23: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 24: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Table 25: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Region

Table 26: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Drug Type

Table 27: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By Application

Table 28: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2026, By End User

Explore Persistence Market Research’s expertise in promulgation of the business !

List of Chart

List of Figures

Figure 01: Injectable Nanomedicines Market Value Share By Region (2018)

Figure 02: Global Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 03: Global Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 04: Global Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 05: Global Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 06: North America Injectable Nanomedicines Market, Snapshot

Figure 07: North America Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 08: North America Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 09: North America Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 10: North America Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 11: North America Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 12: North America Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 13: North America Injectable Nanomedicines Market Attractiveness Analysis, By Country

Figure 14: North America Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 15: North America Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 16: North America Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 17: Latin America Injectable Nanomedicines Market, Snapshot

Figure 18: Latin America Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 19: Latin America Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 20: Latin America Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 21: Latin America Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 22: Latin America Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 23: Latin America Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 24: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Country

Figure 25: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 26: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 27: Latin America Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 28: Europe Injectable Nanomedicines Market, Snapshot

Figure 29: Europe Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 30: Europe Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 31: Europe Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 32: Europe Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 33: Europe Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 34: Europe Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 35: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Country

Figure 36: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 37: Europe Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 38: Europe Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 39: Asia Pacific Injectable Nanomedicines Market, Snapshot

Figure 40: Asia Pacific Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 41: Asia Pacific Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 42: Asia Pacific Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 43: Asia Pacific Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 44: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 45: Asia Pacific Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 46: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Country

Figure 47: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 48: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 49: Asia Pacific Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 50: Middle East & Africa Injectable Nanomedicines Market, Snapshot

Figure 51: Middle East & Africa Injectable Nanomedicines Market Value Share, by Country (2017)

Figure 52: Middle East & Africa Injectable Nanomedicines Market Value Share, by Drug Type (2017)

Figure 53: Middle East & Africa Injectable Nanomedicines Market Value Share, by Application (2017)

Figure 54: Middle East & Africa Injectable Nanomedicines Market Value Share, by End User (2017)

Figure 55: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 56: Middle East & Africa Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 57: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Country

Figure 58: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 59: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 60: Middle East & Africa Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 61: Global Injectable Nanomedicines Market Attractiveness Analysis, By Region

Figure 62: Global Injectable Nanomedicines Market Value Share Analysis, By Region, 2017 & 2026

Figure 63: Global Injectable Nanomedicines Market Attractiveness Analysis, By Drug Type

Figure 64: Global Injectable Nanomedicines Market Value Share Analysis, By Drug Type, 2017 & 2026

Figure 65: Global Injectable Nanomedicines Market Attractiveness Analysis, By Application

Figure 66: Global Injectable Nanomedicines Market Value Share Analysis, By Application, 2017 & 2026

Figure 67: Global Injectable Nanomedicines Market Attractiveness Analysis, By End User

Figure 68: Global Injectable Nanomedicines Market Value Share Analysis, By End User, 2017 & 2026

Figure 69: Global Injectable Nanomedicines Market Size (US$ Mn) Analysis, 2013–2017

Figure 70: Global Injectable Nanomedicines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2026

Figure 71: Global Injectable Nanomedicines Market Absolute $ Opportunity, 2013–2026

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Recommendations

Propylene Glycol Ether Market

The global propylene glycol ether market is estimated to have been valued at US$ 1,604.1 Mn by 2017 end and is expected to reach US$ 2,088.4 Mn by the end of 2026 while expanding at a CAGR of 3.0% over the forecast period. .

2-Ethylhexanol Market

South Asia and Pacific and MEA, are estimated to witness a steady growth spurred by rapid economic development. These regions are estimated to hold a prominent share in the 2-ethylhexanol market during the forecast period..

EMEA Dearomatic Solvents Market

Global De-aromatic solvents market is expected to register a CAGR of 5.0% over the forecast period (2016 – 2024), to reach valuation of US$ 556.0 Mn by 2024.

Behenyl Alcohol Market

The behenyl alcohol market has seen steady demand from the cosmetics industry. Moreover, globally, per capita consumption of cosmetics is increasing at a rate of 3.4% per year.

Our Clients

Our Clients